Altimmune's Pemvidutide Shows Broad MASH Efficacy in Phase 2b Data

Event summary

  • Altimmune presented Phase 2b IMPACT trial data at EASL 2026 showing pemvidutide improved multiple non-invasive MASH markers and fibrosis regression at 24 weeks.
  • 37.8% of patients on pemvidutide 1.2 mg and 22.7% on 1.8 mg achieved concurrent ELF and LSM reductions vs. 8.3% on placebo.
  • AI-based qFibrosis analysis showed 68.6% of 1.2 mg patients and 54.5% of 1.8 mg patients achieved fibrosis stage regression vs. 29.6% on placebo.
  • Company plans to begin PERFORMA Phase 3 trial enrollment in H2 2026.

The big picture

Altimmune's data suggests pemvidutide could address multiple dimensions of MASH, positioning it as a potential first-line therapy. The results come as competition in the MASH space heats up, with multiple candidates targeting different disease mechanisms. The company's ability to execute on its Phase 3 plans will be critical in maintaining its lead position.

What we're watching

Regulatory Pathway
Whether the Breakthrough Therapy and Fast Track designations will accelerate pemvidutide's MASH approval process.
Clinical Validation
How the Phase 3 PERFORMA trial confirms or challenges these Phase 2b results.
Competitive Positioning
The pace at which Altimmune can differentiate pemvidutide in the emerging MASH treatment landscape.